Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Streetwise Reports:

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jan 18, 2022 10:13am

142 Views

Post# 34328097

RE:RE:Streetwise Reports:

So we're now back to 12 cents How far do you see it going.

C10H12N2 wrote:
Those numbers by PennyQueen at Streetwise Capital, as good as they may seem are actually low ball numbers if you use the actual valuation method by Bay Bridge Bio.

Two Phase 1 clinical trials @ $88 Million USD valuation each. Plus One Phase 2 clinical trial @ $249 Million USD equals $415 Million USD Valuation once DMT-Stroke moves to Phase 2 in Q4 2022. As of right now with three Phase 1 clinical trials the valuation is $88 Million USD x 3 equals $264 million USD valuation.

Don't take my words for it, it's calculated by an expert from the following link utilizing a "Drug Valuation Calculator."

Valuing drugs and biotech companies